Small molecules for regenerative medicine
Posted: 20 June 2024 | Drug Target Review | No comments yet
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
In this podcast episode, titled ‘Small molecules for regenerative medicine’, we will be discussing how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy, focusing on degenerative muscle diseases.
This conversation features Frank Gleeson, CEO and co-founder of Satellos, and Dr Michael Rudnicki, co-founder and Chief Discovery Officer at Satellos.
Key discussion points:
- The significance of the discovery of a dystrophin-independent signalling pathway
- How the signalling pathway can be targeted with small molecules to treat Duchenne muscular dystrophy and other muscular disorders
- The potential of small molecule therapeutics targeting stem cell pathways in regenerative medicine
This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About the speakers
Frank Gleeson, CEO and co-founder of Satellos
During his international career, Mr Gleeson has been a key party to building more than 20 biomedical companies and has negotiated financing and M&A transactions of more than $500M. He has co-founded two companies with Dr Michael Rudnicki, including Satellos in 2018, and Verio Therapeutics which was acquired by Fate Therapeutics in 2010. Mr Gleeson has served on numerous Boards of private and public companies, and not-for profit organisations, including Chair of the Stem Cell Network.
Dr Michael Rudnicki, co-founder and Chief Discovery Officer at Satellos
An acknowledged world thought leader and scientific authority on muscle stem cell function and their role in muscle regeneration, in a landmark 2007 Cell paper, Dr Rudnicki was the first to define and characterise a subpopulation as bona fide multipotent stem cells in muscle tissue capable of both self renewal and regeneration, called muscle stem cells or satellite cells. Building on this seminal work, Dr Rudnicki has established a continuous record of foundational findings and discoveries spanning a 25-year research career. In so doing, he has transformed the field’s understanding of the nature and role muscle stem cells play in the lifelong repair and growth processes of skeletal muscle, the body’s largest organ.
Related topics
Drug Discovery Processes, Regenerative Medicine, Small molecule, Small Molecules, Stem Cells, Targets, Therapeutics
Related conditions
degenerative muscle diseases, Duchenne muscular dystrophy (DMD)
Related organisations
Satellos
Related people
Dr Michael Rudnicki (Satellos), Frank Gleeson (Satellos)
